Behavioural Assessment of the A2a/NR2B Combination in the Unilateral 6-OHDA-Lesioned Rat Model: A New Method to Examine the Therapeutic Potential of Non-Dopaminergic Drugs

Pharmacological Treatment of Parkinson Disease

(2014) Barbara S. Connolly et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial

(2014) Robert A Hauser et al.   LANCET NEUROLOGY

Unprecedented Therapeutic Potential with a Combination of A2A/NR2B Receptor Antagonists as Observed in the 6-OHDA Lesioned Rat Model of Parkinson's Disease

(2014) Anne Michel et al.   PLoS One

Maladaptive Plasticity in Levodopa-Induced Dyskinesias and Tardive Dyskinesias: Old and New Insights on the Effects of Dopamine Receptor Pharmacology

(2014) Antonio Cerasa et al.   Frontiers in Neurology

Amantadine's role in the treatment of levodopa-induced dyskinesia

(2013) R. L. Rodnitzky et al.   NEUROLOGY

Continuous drug delivery in early- and late-stage Parkinson’s disease as a strategy for avoiding dyskinesia induction and expression

(2011) P. Jenner et al.   JOURNAL OF NEURAL TRANSMISSION

Striatal plasticity in Parkinson's disease and L-DOPA induced dyskinesia

(2011) M.M. Iravani et al.   PARKINSONISM & RELATED DISORDERS

Single-Dose Administration of MK-0657, an NR2B-Selective NMDA Antagonist, Does Not Result in Clinically Meaningful Improvement in Motor Function in Patients With Moderate Parkinson's Disease

(2009) Carol Addy et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Istradefylline as monotherapy for Parkinson disease: Results of the 6002-US-051 trial

(2009) H.H. Fernandez et al.   PARKINSONISM & RELATED DISORDERS

Progress in Parkinson's disease—Where do we stand?

(2008) André Toulouse et al.   PROGRESS IN NEUROBIOLOGY

Priming for l-dopa-induced dyskinesia in Parkinson’s disease: A feature inherent to the treatment or the disease?

(2008) Agnès Nadjar et al.   PROGRESS IN NEUROBIOLOGY